AzTrials
AzTrials

Chronic Myelogenous LeukemiaPhase 2NCT01003054

Autologous Transplantation for Chronic Myelogenous Leukemia

A Phase 2 study testing Busulfan, Cyclophosphamide and Imatinib Mesylate in people with Chronic Myelogenous Leukemia, run by M.D. Anderson Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical research is to learn if treatment with high-dose busulfan and cyclophosphamide plus autologous bone marrow transplantation followed by treatment with Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML). Objectives: 1. Read more about this study

Who is it for?
Ages Up to 70 years
Conditions the study is for
Chronic Myelogenous Leukemia
What is being tested?
Busulfan, Cyclophosphamide and Imatinib Mesylate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteUnited States
Study dates
Mar 2005to Oct 2009
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 70 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Criteria for hematopoietic stem cell collection and cryopreservation: a- Patients with Philadelphia chromosome positive CML < age 70 who achieve a cytogenetic remission (no Ph+ cells on bone marrow cytogenetics, at least twenty metaphases counted) are eligible for hematopoietic stem cell collection and cryopreservation. b- Patients must have a Zubrod PS <2. c.Creatinine < 1.8 mg/dl d.Serum bilirubin < 1.5 mg/dl e. SGPT < 3 x normal values f. Patients with an HLA identical sibling are eligible if they refuse allogeneic transplantation.
  • Patients are eligible for high dose therapy and autologous transplantation if they meet the following criteria (numbered 2-13): - Cytogenetic relapse characterized by > 10% Ph+ metaphases (by FISH analysis or > 2 of 20 Ph+ metaphases on 2 consecutive cytogenetic studies at least 1 month apart).
  • Cytogenetic relapse (as above) with hematologic remission or chronic phase disease, or
  • Accelerated phase or second or subsequent chronic phase.
  • Availability of stored autologous hematopoietic stem cells collected when the patient was in cytogenetic complete remission (0 of >= 20 metaphases positive for Ph+ cells).A minimum of 0.5 x 10 6 CD34 positive cells/kg or 1 x 10 8 total nucleated cells/Kg must be available.
  • Age < 70 years.
Show all 13Show fewer
  • Zubrod PS <=2.
  • Creatinine < 1.8 mg/dL.
  • Cardiac ejection fraction > 40%.
  • DLCO > 50% of the predicted value.
  • Serum bilirubin < 1.5 mg/dL.
  • SGPT < 3 x normal values.
  • Patients with an HLA identical sibling are eligible if they refuse allogeneic transplantation.

Who cannot join

  • Uncontrolled life-threatening infections or comorbid condition that could impair tolerance to the regimen.
  • HIV positivity.
  • Pregnant or lactating women.
  • Blast crisis (>30% blasts in blood or marrow)
  • Hepatitis B or C positivity.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UT MD Anderson Cancer Center

    Houston, Texas, 77070

Other trials in United States

About this study

Official title: Busulfan, Cyclophosphamide, Imatinib Mesylate and Autologous Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

The goal of this clinical research is to learn if treatment with high-dose busulfan and cyclophosphamide plus autologous bone marrow transplantation followed by treatment with Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML).

Objectives:

  1. To assess the efficacy of high dose busulfan-cyclophosphamide and autologous hematopoietic transplantation with post transplant Imatinib mesylate for the treatment of CML. The primary endpoint of the study is to determine the proportion of patients with CML alive in cytogenetic remission at one year following this treatment.
  2. Secondary endpoints are time to progression and survival.
Read the detailed description

Busulfan and cyclophosphamide are chemotherapy drugs which were designed to kill leukemia cells. An autologous bone marrow transplant is given after treatment with busulfan and cyclophosphamide to help in the recovery of blood and immune cells after this treatment. Imatinib mesylate is a drug which helps to stop the growth of leukemia cells. It is given after the transplant to help kill any remaining leukemia cells.

Before treatment, you will have a complete physical exam. You will have approximately 4 tablespoons of blood drawn for tests to check on the status of the disease, to check organ functions, and to check for infectious diseases (hepatitis, HIV, etc.). You will have a sample of bone marrow collected. To collect a bone marrow sample, an area of the hip or chest bone is numbed with anaesthetic and a small amount of bone marrow is withdrawn through a large needle. All of these tests are being done to make sure you are eligible for this treatment. If you are found to have a "blast crisis," you will not be eligible to continue on this study.

If you are eligible or if it has not already been done recently, you will be taken to the operating room and have around 4-6 cups of bone marrow collected. The procedure will be performed under general anesthesia. The procedure is similar to the bone marrow collection at the start of the study, however, more bone marrow will be collected. The bone marrow that is collected will be frozen and stored to be given back to you after high dose chemotherapy. Before the procedure, you will be asked to donate blood (if possible). This blood will be given back to you after the procedure to replace the bone marrow that was collected. You may also need a blood transfusion from another donor.

For patients who cannot undergo the procedure of bone marrow harvesting or if not enough bone marrow was collected during the bone marrow harvesting procedure, stem cells may be collected from the blood. Normally, there are very few stem cells in the blood. Most of them are in the bone marrow. To help move or "mobilize" the cells needed from your bone marrow to your blood, you will be given injections under the skin once a day of a drug called G-CSF. The injections may given by a nurse in the hospital, in the outpatient setting, or you may learn how to give the injection yourself. Blood samples (1 tablespoon) will be drawn every day to see if there are enough stem cells in your blood. After 4-6 days of treatment with G-CSF, you will undergo a procedure called leukapheresis. This procedure is similar to donating blood to a blood bank. Blood is collected and run through a machine that processes the blood and separates the cells needed for transplantation, giving the rest back to you. The separated cells are frozen and stored to give back you after high dose chemotherapy. You may need up to 3 leukapheresis procedures to collect enough cells.

Patients who had adequate amounts of their bone marrow or blood stem cells harvested in the past will not need additional harvesting of stem cells.

At a future time when the leukemia shows signs of growth, you will have a catheter (small, flexible tube) inserted under the collar bone into a large vein in the chest. This catheter will allow the chemotherapy drugs, fluids, and other medications to be given more easily. You will have approximately 4 tablespoons of blood drawn for tests to check on the status of the disease, to check organ functions, and to check for infectious diseases (hepatitis, HIV, etc.). You will have a sample of bone marrow collected. You will also have heart (cardiac ejection fraction) and lung function tests.

You will be admitted to the hospital to receive high dose chemotherapy. You will be given busulfan by continuous injection (using the catheter) for 4 days, then you will be given cyclophosphamide by a continuous injection (using the catheter) for 2 days. The amount of busulfan you receive may be adjusted to help decrease the risk of developing side effects. You may also receive antibiotics, fluids, and other medications if your doctor feels it is necessary.

After high dose chemotherapy, you will be given your stored bone marrow or blood stem cells back ("transplant"). They will be given back to you through the catheter to help restore blood production and immunity after high dose chemotherapy. To help speed up the recovery of white blood cells, you will also be given G-CSF by injection under the skin daily until the white blood count has recovered (usually 2 to 3 weeks). You may also receive antibiotics, fluids, and other medications if your doctor feels it is necessary. Blood tests are repeated several times per week until blood counts are fully recovered and any side effects of the high dose therapy have resolved.

After your blood counts have recovered, you will begin treatment with imatinib mesylate by mouth for up to 1 year. You may also receive medications to help prevent infections for around 6 months after the transplant. These medications are usually pills to help prevent pneumonia and viral infections. While you are taking imatinib mesylate you will have blood collected (1- 4 tablespoons) for routine tests . The frequency of these blood collections will depend on your medical condition.

Around 1, 3, 6, 12, 18, and 24 months after transplant, you will have check-up visits. At these visits, you will have blood collected (1- 4 tablespoons) for routine blood tests and have a sample of bone marrow collected for tests. This bone marrow collection will be repeated 3, 4, and 5 years after the transplant procedure.

This is an investigational study. All of the drugs used in this study are FDA approved and are commercially available. Up to 50 participants will take part in this study. All will be enrolled at M. D. Anderson.

Being tested
Busulfan, Cyclophosphamide, Imatinib Mesylate, Autologous Stem Cell Transplantation
Keywords
Leukemia, CML, Busulfan, Busulfex, Myleran, Cyclophosphamide, Cytoxan, Neosar, Imatinib Mesylate, Gleevec, Autologous Stem Cell Transplantation, Stem Cell Transplant
Medical subject headings
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BusulfanDrug

    Also called Busulfex, Myleran

    130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)

  • CyclophosphamideDrug

    Also called Cytoxan, Neosar

    60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)

  • Imatinib MesylateDrug

    Also called Imatinib, Gleevec, STI571, NSC-716051

    Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.

  • Autologous Stem Cell TransplantationProcedure or surgery

    Also called Stem Cell Transplant

    Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.

Study groups in NCT01003054
Study groupRoleWhat they receive
Autologous TransplantationExperimentalBusulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
Receives: Drug: Busulfan; Drug: Cyclophosphamide; Drug: Imatinib Mesylate; Procedure: Autologous Stem Cell Transplantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with CML alive in cytogenetic remission at one year following treatment

    Cytogenetic complete remission confirmed via bone marrow examination for morphology, cytogenetics or Fluorescence in situ hybridization (FISH).

    Measured: Baseline to 1 Year post treatment, up to 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 2009 (estimated)
  2. Study startMar 2005
  3. Primary completionDec 2007
  4. Study completionOct 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01003054
Sponsor's protocol ID
ID02-672
Status last verified
Oct 2011
First submitted
26 Oct 2009
Last updated
2 Nov 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Busulfan, Cyclophosphamide and Imatinib Mesylate in people with Chronic Myelogenous Leukemia, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with CML alive in cytogenetic remission at one year following treatment (time frame: Baseline to 1 Year post treatment, up to 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in